ReviewPediatric nephrology (Berlin, Germany)2011
Renal amyloidosis in children.
Review in Pediatric nephrology (Berlin, Germany), 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 83 citations in OpenAlex.
- Long-term efficacy and safety of canakinumab in patients with colchicine-resistant familial Mediterranean fever: results from the randomised phase III CLUSTER trial.Annals of the rheumatic diseases · 2020Trial
- Renal hemodynamic alterations assessed by doppler ultrasonography in familial mediterranean fever patients without overt renal disease: a cross-sectional study.BMC nephrology · 2026Observational
- Amyloidosis in Childhood: A Review of Clinical Features and Comparison with Adult Forms.Journal of clinical medicine · 2024Review
- Evaluation of Hematological Parameters as Markers for Subclinical Inflammation in Adults with Familial Mediterranean Fever.Middle East journal of digestive diseases · 2024Article
- bDMARD can prevent the progression of AA amyloidosis to end-stage renal disease.Annals of the rheumatic diseases · 2024Article
- IL-1 Inhibitors in the Treatment of Familial Mediterranean Fever: Treatment Indications and Clinical Features in a Large Real-World Cohort.Journal of clinical medicine · 2024Article
- Pan-Immune-Inflammation Value Could Be a New Marker to Predict Amyloidosis and Disease Severity in Familial Mediterranean Fever.Diagnostics (Basel, Switzerland) · 2024Article
- Effectiveness of Colchicine or Canakinumab in Japanese Patients with Familial Mediterranean Fever: A Single-Center Study.Journal of clinical medicine · 2023Article
- The pyrin inflammasome, a leading actor in pediatric autoinflammatory diseases.Frontiers in immunology · 2023Review
- Intrinsic Kidney Pathology in Children and Adolescents Following COVID-19 Vaccination: A Systematic Review.Children (Basel, Switzerland) · 2022Review
- Kidney disease in a child with familial Mediterranean fever: Answers.Pediatric nephrology (Berlin, Germany) · 2022Article
- The effectiveness of anti-interleukin-1 therapy on subclinical inflammation parameters during the attack-free period in familial Mediterranean fever patients: A case-control study.Turkish journal of medical sciences · 2022Article
- Intrinsic Kidney Pathology Following COVID-19 Infection in Children and Adolescents: A Systematic Review.Children (Basel, Switzerland) · 2021Review
- Renal AA Amyloidosis as Rare Presentation of Tumor Necrosis Factor Receptor-Associated Periodic Syndrome in Pediatric Patient.Kidney international reports · 2021Article
- Monogenic Autoinflammatory Diseases: State of the Art and Future Perspectives.International journal of molecular sciences · 2021Review
- Successful use of tocilizumab in amyloidosis secondary to systemic juvenile idiopathic arthritis.Rheumatology international · 2020Review
- Periodic fever syndromes and the autoinflammatory diseases (AIDs).Journal of translational autoimmunity · 2020Review
- What's new in autoinflammation?Pediatric nephrology (Berlin, Germany) · 2019Review
- Evaluation of hematological parameters in children with FMF.Clinical rheumatology · 2019Article
- A Comprehensive Overview of the Hereditary Periodic Fever Syndromes.Clinical reviews in allergy & immunology · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Renal amyloidosis is a detrimental disease caused by the deposition of amyloid fibrils. A child with renal amyloidosis may present with proteinuria or nephrotic syndrome. Chronic renal failure may follow. Amyloid fibrils may deposit in other organs as well. The diagnosis is through the typical appearance on histopathology. Although chronic infections and chronic inflammatory diseases used to be the causes of secondary amyloidosis in children, the most frequent cause is now autoinflammatory diseases. Among this group of diseases, the most frequent one throughout the world is familial Mediterranean fever (FMF). FMF is typically characterized by attacks of clinical inflammation in the form of fever and serositis and high acute-phase reactants. Persisting inflammation in inadequately treated disease is associated with the development of secondary amyloidosis. The main treatment is colchicine. A number of other monogenic autoinflammatory diseases have also been identified. Among them cryopyrin-associated periodic syndrome (CAPS) is outstanding with its clinical features and the predilection to develop secondary amyloidosis in untreated cases. The treatment of secondary amyloidosis mainly depends on the treatment of the disease. However, a number of new treatments for amyloid per se are in the pipeline.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.